Literature DB >> 10779163

Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector.

D Maione1, M Wiznerowicz, P Delmastro, R Cortese, G Ciliberto, N La Monica, R Savino.   

Abstract

Helper-dependent (HD) adenoviral (Ad) vectors, in which all viral coding sequences are deleted, have been generated. We show here that intravenous delivery of a mouse EPO (mEPO) expression cassette cloned in an HD vector in immunocompetent mice is effective and long lasting, but not permanent. A precise dose-response relationship between the dose of injected virus and stable EPO serum levels was observed, together with a 100-fold increase in gene expression per infectious particle when compared with a first-generation Ad vector bearing the same cassette. As a direct consequence, therapeutic increases in hematocrit that lasted more than 6 months were achieved with minute amounts of virus, which caused no detectable production of neutralizing antibodies. Intravenous readministration of the HD-mEPO vector in the same mice was as effective as in naive animals without any need for prior immunosuppression. Finally, HD-mEPO injection in subtotally nephrectomized rats improved the anemic status induced by surgery. HD Ad vectors are thus excellent tools for EPO gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779163     DOI: 10.1089/10430340050015473

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

1.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.

Authors:  L Aurisicchio; P Delmastro; V Salucci; O G Paz; P Rovere; G Ciliberto; N La Monica; F Palombo
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Helper-dependent adenoviral vectors in experimental gene therapy.

Authors:  Alicja Józkowicz; Józef Dulak
Journal:  Acta Biochim Pol       Date:  2005-08-04       Impact factor: 2.149

5.  Adenoviral p53 gene transfer inhibits human Tenon's capsule fibroblast proliferation.

Authors:  K T M Johnson; F Rödicker; K Heise; C Heinz; K-P Steuhl; B M Pützer; T Hudde
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

6.  Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.

Authors:  Elena Fattori; Manuela Cappelletti; Paola Lo Surdo; Alessandra Calzetta; Claus Bendtsen; Yan G Ni; Shilpa Pandit; Ayesha Sitlani; Giuseppe Mesiti; Andrea Carfí; Paolo Monaci
Journal:  J Lipid Res       Date:  2012-05-19       Impact factor: 5.922

7.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector.

Authors:  Luigi Aurisicchio; Amedeo De Tomassi; Nicola La Monica; Gennaro Ciliberto; Cinzia Traboni; Fabio Palombo
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.

Authors:  Jifeng Sun; Yarong Wang; Jie Yang; Dewei Du; Zhanting Li; Junxia Wei; Angang Yang
Journal:  Exp Mol Med       Date:  2012-11-30       Impact factor: 8.718

10.  Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment.

Authors:  Emmanuelle E Fabre; Pascal Bigey; Yves Beuzard; Daniel Scherman; Emmanuel Payen
Journal:  Genet Vaccines Ther       Date:  2008-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.